Innate Pharma SA Price to Free Cash Flow Ratio 2012-2023 | IPHYF

Innate Pharma SA price to free cash flow ratio from 2012 to 2023. Price to free cash flow ratio can be defined as

Innate Pharma SA Price to Free Cash Flow Ratio 2012-2023 | IPHYF

Innate Pharma SA price to free cash flow ratio from 2012 to 2023. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$79.5B
Takeda Pharmaceutical (TAK)$43.4B
Merck (MKKGY)$21B
Astellas Pharma (ALPMY)$20.3B
Sandoz Group AG (SDZNY)$19.9B
United Therapeutics (UTHR)$17.9B
Summit Therapeutics (SMMT)$16.1B
Neurocrine Biosciences (NBIX)$12.9B
Shionogi (SGIOY)$12.3B
Catalent (CTLT)$10.8B
Jazz Pharmaceuticals (JAZZ)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.4B
Orion OYJ (ORINY)$6.8B
Corcept Therapeutics (CORT)$6.2B
Ionis Pharmaceuticals (IONS)$6.1B
Crinetics Pharmaceuticals (CRNX)$4.8B
PTC Therapeutics (PTCT)$3.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.8B
Dyne Therapeutics (DYN)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.8B
Arrowhead Pharmaceuticals (ARWR)$2.7B
Soleno Therapeutics (SLNO)$2.6B
NewAmsterdam Pharma (NAMS)$2.2B
Recursion Pharmaceuticals (RXRX)$2.2B
Centessa Pharmaceuticals (CNTA)$1.9B
Harrow (HROW)$1.8B
Evotec AG (EVO)$1.7B
Ocular Therapeutix (OCUL)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.7B
ARS Pharmaceuticals (SPRY)$1.7B